| (USD) | Mar 2024 | Q/Q |
|---|---|---|
| Revenue | 17.1MM | -36% |
| Gross Profit | 12.2MM | - |
| Cost Of Revenue | 4.9MM | +70% |
| Operating Income | -11.9MM | -4316% |
| Operating Expenses | 24.1MM | - |
| Net Income | -11.5MM | +60% |
| R&D | 11.2MM | +0% |
| G&A | 12.9MM | +6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Codexis ( NASDAQ:CDXS ) First Quarter 2024 Results Key Financial Results Revenue: US$17.1m (up 32% from 1Q 2023). Net...
Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call Transcript May 2, 2024 Codexis, Inc. beats earnings expectations. Reported EPS is $-0.1647, expectations were $-0.17. Codexis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Codexis’ First Quarter 2024 […]
Q1 2024 Codexis Inc Earnings Call
Explore key financial outcomes and strategic milestones from Codexis Inc's first quarter of 2024, reflecting robust growth and promising developments.
Despite a Net Loss, Codexis Demonstrates Strong Revenue Growth and Strategic Milestones
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today an
Key Insights Given the large stake in the stock by institutions, Codexis' stock price might be vulnerable to their...
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relation
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platformREDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agricu
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...